Teva Pharmaceutical Industries Ltd. has signed a collaboration option to license and invest in Cocrystal Discovery Inc. (CDI), a biopharma company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases. The investment in CDI will be used to continue its development program of antiviral drugs that target viral replication enzymes. CDI is using its technologies to develop oral, once-a-day, broad-spectrum antivirals for the ...